Brammer Bio has completed renovations at its gene therapy manufacturing facility in Cambridge, MA amid industrywide capacity concerns as more biologics enter late-stage clinical trials.
The UK government has outlined its industrial strategy as it prepares to leave the European Union and boasts of investments and collaborations driving the life science sector.
Thermo Fisher will up its list prices by an average of 3.3% across much of its early-stage bioproduction product range, reflecting changing market conditions.
Physicians and patients still lack information about biosimilars says an industry consultant, despite efforts from advocacy groups and national healthcare systems.
Fibrocell Science will make its gene therapy candidate FCX-007 from a facility in Pennsylvania previously dedicated to making its autologous personalised cosmetic Laviv (azficel-T).
Pall Corporation has launched a monoclonal antibody clarification platform without centrifugation or process additives to support cell cultures of up to 2,000L.
Antibody-drug conjugate (ADC) developers are at risk of aggregation issues caused by the hydrophobic nature of next-generation linker-payloads, says ADC Bio.
GE Healthcare opened its European Innovative Design and Advanced Manufacturing Technology Center last month. Biopharma-Reporter took a visit to Uppsala, Sweden to find out more.
Samsung Bioepis has received European Commission approval for Ontruzant, its version of Roche’s best-selling breast cancer mAb Herceptin (trastuzumab).
Janssen has withdrawn a lawsuit against Samsung Bioepis alleging infliximab manufacturing patent infringements after receiving process information from the Korean drugmaker.
Peregrine Pharmaceuticals will become a pure-play CDMO under the name Avid Bioservices and is looking to sell or license its pipeline, including investigational monoclonal antibody bavituximab.
Mvasi has been recommended for approval in Europe, but a duplicate marketing authorisation application for an Avastin (bevacizumab) biosimilar has been withdrawn by Amgen.
Single-use demand grew so fast vendors were unable to keep up, says MilliporeSigma which has since tackled this through investments and a standardised offering.
By InVitria launches xeno-free service within $5.2bn media market
Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.
Takeda has partnered with Portal Instruments to develop a needle-free drug delivery device for biologic medicines, starting with the former’s Entyvio (vedolizumab).
Sotera Health – the recently rebranded Sterigenics International – will add extractables and leachables testing services to its Nelson Labs business with the acquisition of Toxikon Europe NV.
Standardising disposable bioreactor technology – starting with the buffer bag – will help ensure single-use supply chain security, says biomanufacturing consultant David Wolton.
Following a ¥14bn ($125m) investment in April, Fujifilm Corporation has committed a further ¥3.2bn across its biologics contract manufacturing business.
Pall Corporation will equip WuXi Biologics’ continuous bioprocess laboratory in Shanghai, China, which the latter said would expand process scale and reduce manufacturing costs.
Heavy investment in quality control, quality assurance and dedicated equipment is likely to keep CAR T-cell manufacturing in-house, says Juno Therapeutics.
Nearly half the respondents of our second state of the global biomanufacturing survey believe we are too reliant on Chinese Hamster Ovary (CHO) expression systems.
